Submitted by Anonymous (not verified) on 8 April 2026 - 12:47
Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 17, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 17, Status: Authorised